Showing results 16 to 24 of 24
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
2020 | |||
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg Journal:Science Translational Medicine | 2017 | ||
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers Journal:Clinical Pharmacology in Drug Development | 2017 | ||
2021 | |||
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology | 2019 | ||
2020 | |||
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent Journal:Antiviral Research | 2015 | ||
T1653 mutation in the box α increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C Infection Journal:Clinical Infectious Diseases | 2006 | ||
2008 |